Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R, Bufi E, Belli P, Scrofani AR, Petta F, Borghetti A, Marazzi F, Valentini V, Manfredi R. Rella R, et al. Among authors: borghetti a. Diagn Interv Imaging. 2022 Oct;103(10):486-494. doi: 10.1016/j.diii.2022.04.004. Epub 2022 May 15. Diagn Interv Imaging. 2022. PMID: 35585020 Free article.
Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
Passerotto RA, Lamanna F, Salvo PF, Iannone V, Steiner RJ, Carbone A, Farinacci D, D'Angelillo A, Baldin G, Ciccullo A, Di Giambenedetto S, Torti C, Borghetti A. Passerotto RA, et al. Among authors: borghetti a. Antivir Ther. 2024 Dec;29(6):13596535241306467. doi: 10.1177/13596535241306467. Antivir Ther. 2024. PMID: 39698926 Free article.
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d'Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S. Baldin G, et al. Among authors: borghetti a. Int J Antimicrob Agents. 2019 Dec;54(6):728-734. doi: 10.1016/j.ijantimicag.2019.09.002. Epub 2019 Sep 12. Int J Antimicrob Agents. 2019. PMID: 31521809 Free article.
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
Baldin G, Ciccullo A, Lombardi F, D'Angelillo A, Dusina A, Emiliozzi A, Farinacci D, Moschese D, Picarelli C, Borghetti A, Di Giambenedetto S. Baldin G, et al. Among authors: borghetti a. AIDS Res Hum Retroviruses. 2021 Jun;37(6):429-432. doi: 10.1089/AID.2020.0219. Epub 2020 Dec 30. AIDS Res Hum Retroviruses. 2021. PMID: 33280486
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Lombardi F, Belmonti S, Borghetti A, Fabbiani M, Marchetti S, Tamburrini E, Cauda R, di Giambenedetto S. Lombardi F, et al. Among authors: borghetti a. J Antimicrob Chemother. 2020 Jun 1;75(6):1599-1603. doi: 10.1093/jac/dkaa058. J Antimicrob Chemother. 2020. PMID: 32101614
433 results